The aim of this national pragmatic observational study is to investigate whether the use of new diagnostic imaging modalities facilitates disease stratification that can potentially predict treatment response, relapse risk and complications and hence guide management strategies to improve disease control and reduce disease and treatment related damage.
Eligibility
Sex
ALL
Min age
50 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Are diagnosed with GCA or PMR within the last 5 years
* Diagnosis is established by or confirmed by a rheumatologist (clinical expert opinion)
* Speak and understand Danish
* Are able to give signed and dated informed consent
Exclusion Criteria:
* Denies or are not able to give informed consent
* Are diagnosed with other systemic autoimmune diseases that out-rules the diagnosis of GCA or PMR
Primary outcome measure(s)
Cumulative glucocorticoid doses compared between patients with cranial GCA and patients with Large Vessel-GCA — From date of diagnosis with GCA until one year after. Assessed yearly up to 120 months based on redeemed prescriptions
Trial sites (2)
Facility
City
Region
Status
Led og Bindevævssygdomme, Aarhus University Hospital
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.